Molecular Partners (NasdaqGS:MOLN) FY Conference Transcript

Summary of Molecular Partners FY Conference Call Company Overview - Company Name: Molecular Partners (NasdaqGS:MOLN) - Focus: Development of DARPin candidates, particularly in the field of radiotherapy - Financial Position: Over $100 million in cash (approximately CHF 93 million) available for investment in R&D [4][30] Key Industry Insights - Biotech Sector Outlook: Increased confidence in a turnaround for the biotech sector in 2026, following a challenging period [3] - Radiotherapy Market: Positive feedback and renewed interest in radiotherapy, highlighted by the successful IPO of Aktis Oncology [3] Core Product Focus - Primary Candidate: MP0712, a DLL3-targeted DARPin, is expected to drive value creation in the upcoming year [4][6] - Pipeline Overview: Emphasis on MP0712, with additional focus on MPO 317 and MPO 533, which are also in development [6][11] Product Development and Clinical Trials - MPO 317: Initially considered a dead program, it has been revived due to promising phase one data showing immune activation in colorectal carcinoma. A new trial will involve 75 patients across 11 centers in France, with results expected in 2027 [10][11] - MPO 533: A multispecific DARPin targeting acute myeloid leukemia (AML), designed to eradicate residual disease clones. The focus will be on low disease burden patients [11][12] Radiotherapy Mechanism - Mechanism of Action: MP0712 utilizes a DARPin vector linked to a radioisotope (Lead-212) to target DLL3 in small cell lung cancer. The approach aims to combine the efficacy of T cell engagers with the durability of antibody-drug conjugates (ADCs) [14][16][18] - Clinical Strategy: The company plans to initiate a phase one dose escalation trial, starting with a 75-megabecquerel dose, with a fast-to-market strategy for small cell lung cancer [27][30] Safety and Efficacy Considerations - Safety Profile: The rapid decay of Lead-212 is expected to result in minimal hematological toxicity, with recovery of blood values anticipated [34][37] - Patient Experience: Radiotherapy is expected to offer a better quality of life for patients compared to T cell engagers, which often cause acute side effects [37] Partnerships and Collaborations - Orano Med Partnership: A 50/50 partnership focused on the supply of Lead-212, with Orano Med providing a robust supply chain and infrastructure for the isotope [40][43] - Future Collaborations: The company is open to exploring partnerships for other isotopes, such as actinium, to enhance treatment options [45][46] Future Directions - Expansion of Indications: Beyond small cell lung cancer, there are plans to explore other neuroendocrine tumors with DLL3 expression [47][48] - Innovative Imaging Techniques: The use of imaging agents to select patients with DLL3 expression is seen as pivotal for maximizing treatment efficacy [48] Conclusion - Focus for 2026: The primary focus will be on MP0712, with expectations for first-in-human results and safety data in the first half of the year, followed by activity data in the second half [30]